Vaxcyte (PCVX) Income from Continuing Operations (2019 - 2026)
Vaxcyte (PCVX) reported Income from Continuing Operations of 319240000.0 for Q1 2026, down 115.91% year-over-year from 2006554494.13 in Q1 2025, and down 28.81% quarter-over-quarter from 247832000.0 in Q4 2025.
Vaxcyte (PCVX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has 8 years of Income from Continuing Operations data on file, last reported at 319240000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 319240000.0, down 115.91% year-over-year; the trailing twelve-month figure through Mar 2026 was 975339000.0 (down 89.53% YoY), and the FY2025 annual result was 803957000.0, down 74.94% from the prior year.
- Income from Continuing Operations slipped to 319240000.0 in Q1 2026 per PCVX's latest filing, from 247832000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 39087000.0 in Q1 2022 and troughed at 319240000.0 in Q1 2026.
- A 5-year average of 130105058.82 and a median of 111867000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations sank 168.73% in 2022, then increased 29.81% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 79940000.0 in 2022, then plunged by 124.05% to 179108000.0 in 2023, then advanced by 29.81% to 125711000.0 in 2024, then sank by 97.14% to 247832000.0 in 2025, then decreased by 28.81% to 319240000.0 in 2026.
- Business Quant data shows PCVX's Income from Continuing Operations at 319240000.0 in Q1 2026, 247832000.0 in Q4 2025, and 213121000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Vaxcyte | 6.34 Bn | 6.34 Bn | - | -319.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -319.24 Mn |
| Dec 31, 2025 | -247.83 Mn |
| Sep 30, 2025 | -213.12 Mn |
| Jun 30, 2025 | -195.15 Mn |
| Mar 31, 2025 | -147.86 Mn |
| Dec 31, 2024 | -125.71 Mn |
| Sep 30, 2024 | -111.87 Mn |
| Jun 30, 2024 | -129.17 Mn |
| Mar 31, 2024 | -92.81 Mn |
| Dec 31, 2023 | -179.11 Mn |
| Sep 30, 2023 | -94.53 Mn |
| Jun 30, 2023 | -70.70 Mn |
| Mar 31, 2023 | -60.80 Mn |
| Dec 31, 2022 | -79.94 Mn |
| Sep 30, 2022 | -57.39 Mn |
| Jun 30, 2022 | -47.49 Mn |
| Mar 31, 2022 | -39.09 Mn |
| Dec 31, 2021 | -29.75 Mn |
| Sep 30, 2021 | -26.86 Mn |
| Jun 30, 2021 | -23.64 Mn |